Ann: Bubs Q4 FY24 Quarterly Activity and Cashflow Statement, page-30

@Iamanonymous

Yes well my sources say you're full of it.

My unsubstantiated sources vs. yours I guess.

So far you've:

-claimed production was being cut amid plunging demand (weirdly sales grew)

-promised to send photos of massive inventory overhang and never delivered

- claimed the inside scoop on new products that were already publicly announced 6 months earlier

For an insider you sound a lot like an outsider trying very poorly to look like an insider.

Anyway regarding FDA, if all goes well and they receive approval, it won't allow them to do anything they aren't already doing. All other companies who have temporary discretion are going through the same process. So I would argue approval is mostly priced in and there's not much it will change.